FCRL5 and Miyoshi myopathy: An important issue concerning the CAR-T therapy against FcRH5 is the potentially inhibitory impact of sFcRH5 antigens on the ability to target membrane-bound FcRH5, particularly in MM patients with high levels of sFcRH5 present in the circulation, as reported by others24.